PROTAC BRD9 Degrader-7

PROTAC BRD9 Degrader-7 is an orally active, selective BRD9 PROTAC degrader (DC50 = 1.02 nM) . PROTAC BRD9 Degrader-7 mediates BRD9 degradation via the ubiquitin-proteasome system. PROTAC BRD9 Degrader-7 exhibits proliferation inhibitory activity in the MV4-11 cells. PROTAC BRD9 Degrader-7 can be used in the research of acute myeloid leukemia and other related malignancies. (Pink: BI 7271: HY-123616, Blue: 5-Aminothalidomide: HY-W023573, Blue + Black: Thalidomide-5-piperazine: HY-W834174, Black: N, N'-Dimethylpiperazine: HY-W539783) [1].

Product Specifications

CAS Number

[3056013-04-5]

UNSPSC

12352005

Target

Epigenetic Reader Domain; PROTACs

Type

Reference compound

Related Pathways

Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/protac-brd9-degrader-7.html

Purity

99.29

Solubility

DMSO : 70 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N(C)C=C1C2=CC(OC)=C(CN3CCN(C4=CC=C5C(C(N(C6C(NC(CC6)=O)=O)C5=O)=O)=C4)CC3)C(OC)=C2)C7=C1C=CC=C7

Molecular Formula

C36H35N5O7

Molecular Weight

649.69

References & Citations

[1]Jingyu Zhang, et al. Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia, European Journal of Medicinal Chemistry, Volume 262, 2023, 115872.